Beyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers an Alzheimer’s ...

Congress is one of the biggest events on the cancer research calendar, where clinical results can reshape treatment decisions ...

AI can already reduce administrative work, improve decision-making and streamline parts of clinical development. But its ...

Inspired by technology and ­insights gleaned from cancer research, Europe is leading the quest for a new generation of ...

Sweden's Spago Nanomedical will ask shareholders on Nov. 19 to approve delisting from Nasdaq First North, arguing that its ...

Italy's Menarini Group will pay Maryland biotech Georgiamune $45 million (€40 million) in upfront and near-term payments, in ...

Swiss big pharma Roche has agreed to license ZW209, an experimental cancer immunotherapy from Vancouver-based Zymeworks, for ...

British rare disease specialist Ambrose Healthcare has acquired Dutch biotech AM-Pharma for up to €161 million, adding an enzyme replacement therapy to its pipeline and a development base in Utrecht.

Swedish private equity firm EQT wants to acquire diagnostics specialist Qiagen for €10.8 billion, or €46.50 per share. The company’s leadership unanimously supports the sale. Completion is planned for ...

At the IZB in Martinsried, Invitris is developing a cell-free platform to turn ­digital sequences into proteins, antibodies ...

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...

The Swiss pharmaceutical group has agreed to another, deeper ADC partnership with China’s Hansoh Pharma, with potential ...